Also indexed as: Cis-9-Cetyl Myristoleate, CMO
Cetyl myristoleate (CMO) is the common name for cis-9-cetyl myristoleate. CMO was
discovered in 1972 by Harry W. Diehl, Ph.D., a researcher at the National Institutes of
Health. At the time, Dr. Diehl was responsible for testing anti-inflammatory drugs on lab
animals. In order for him to test the drugs, he first had to artificially induce arthritis in
the animals by injecting a heat-killed bacterium called Freund’s adjuvant. Dr. Diehl
discovered that Swiss albino mice did not get arthritis after injection of Freund’s
adjuvant. Eventually, he was able to determine that cetyl myristoleate was the factor present
naturally in mice that was responsible for this protection. When CMO was injected into various
strains of rats, it offered the same protection against arthritis.1
Where is it found?
Cetyl myristoleate is found in certain animals, including cows, whales, beavers, and mice.
As a nutritional supplement it is found in a highly purified, refined form in capsules and
tablets. CMO is also available in creams and lotions for topical application.
CMO has been used in
connection with the following conditions (refer to the individual
health concern for complete information):
Who is likely to be deficient?
As cetyl myristoleate is not an essential nutrient, no deficiency state exists.
How much is usually taken?
Generally, CMO is taken in the amount of 400 to 500 mg daily for 30 days.
Are there any side effects or interactions?
No side effects or drug interactions have been reported.
At the time of writing, there were no well-known drug interactions
with cetyl myristoleate.
1. Diehl HW, May EL. Cetyl myristoleate isolated from Swiss albino mice:
an apparent protective agent against adjuvant arthritis in rats. J Pharm Sci